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Aromatase is essential for estrogen production and is the target of aromatase inhibitors, themost
effective endocrine treatment for postmenopausal breast cancer. Peripheral tissues in women,
including the breast, express aromatase via alternative promoters. Femalemice lack the promoters
that drive aromatase expression in peripheral tissues; thus, we generated a transgenic humanized
aromatase (Aromhum) mouse line containing a single copy of the human aromatase gene to study
the linkbetweenaromataseexpression inmammaryadipose tissueandbreastpathology.Aromhum
miceexpressedhumanaromatase, drivenby theproximal humanpromoters II and I.3 and thedistal
promoter I.4, in breast adipose fibroblasts and myoepithelial cells. Estrogen levels in the breast
tissueofAromhummicewerehigher than inwild-typemice,whereas circulating levelswere similar.
Aromhum mice exhibited accelerated mammary duct elongation at puberty and an increased in-
cidence of lobuloalveolar breast hyperplasia associated with increased signal transducer and ac-
tivator of transcription-5 phosphorylation at 24 and 64 wk. Hyperplastic epithelial cells showed re-
markably increasedproliferative activity. Thus,wedemonstrated that thehumanaromatasegene can
be expressed via its native promoters in a wide variety of mouse tissues and in a distribution pattern
nearly identical to thatofhumans. Locally increased tissue levels, butnot circulating levels, of estrogen
appearedtoexerthyperplasticeffectsonthemammarygland.Thisnovelmousemodelwillbevaluable
for developing tissue-specific aromatase inhibition strategies. (Endocrinology 153: 2701–2713, 2012)
Aromatase, encoded by a single gene, is essential forestrogen production. Estrogens exert their effects by
binding to twodistinct receptors, estrogen receptor (ER)-
and ER (1, 2). Aromatase and epithelial ER expression
are required for normal mammary gland development in-
volving ductal elongation and outgrowth during puberty
(3, 4). Aromatase and estrogen are also involved in the
development of hormone-dependent breast cancer, and
aromatase inhibitors are the most effective endocrine
treatment for postmenopausal breast cancer (5, 6). The
causal relationship between estrogen and breast cancer
has been well documented in studies of several breast
cancer cell lines (7). Ligand-activated ER acts in the
nucleus as a transcriptional factor or interacts with and
activates cytoplasmic signaling molecules including c-
Src, signal transducer and activator of transcription
(Stat), ERK, and phosphatidylinositol 3-kinase (PI3K)/
Akt (8, 9).
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Both human and mouse aromatase genes comprise 10
exons, nine of which are coding exons (II-X) that span
approximately 30 kb. A number of alternative noncoding
first exons are expressed in a tissue-specific manner and
are spliced onto a common junction upstreamof the trans-
lation start site, resulting in the synthesis of identical aro-
matase proteins regardless of the first exon used (5, 10). In
humans, 10 alternative tissue-specific first exons have
been identified in various tissues: exons I.1, I.2, and I.2a in
placenta (93, 78, and 13 kb); I.4 in adipose tissue
and skin (73 kb); I.5 in fetal tissues (43 kb); I.7 in
endothelial cells (36 kb); I.f in brain (33 kb); I.6 in
bone (1kb); I.3 in breast fat proximal to cancer (0.3
kb); and PII in gonads (0.1 kb) (11). In contrast to the
human gene, there are only two tissue-specific untrans-
lated first exons in the female mouse aromatase gene: a
gonadal-specific exon (0.1 kb) and a brain-specific exon
(35.5 kb) (12–14). Compared with mice, then, women
express aromatase via alternatively used promoters in a
number of additional peripheral tissues (e.g. breast adi-
pose), giving rise to drastically distinct tissue distribution
patterns of aromatase expression.
Thus far, two transgenicmouse lines expressing human
aromatase have been reported: mice expressing human
aromatase driven by the mouse mammary tumor virus-
long-terminal repeatpromoter (int-5/aromatase) andmice
expressing human aromatase driven by the human ubiq-
uitin C promoter (15). Int-5/aromatase female mice ex-
hibit mammary duct hyperplasia, ductal dysplastic le-
sions, alveolar hyperproliferation, and fibroadenomas
(16). The phenotype of the mice expressing human aro-
matase driven by the human ubiquitin C promoter is char-
acterized by mammary hyperplasia in 15-month-old fe-
males (15, 17). Although these two animal models have
helped in understanding the molecular mechanisms in-
volved in the formation of the mammary glands and the
development of breast cancer, they do not mimic human
aromatase expression patterns in peripheral tissues driven
by native promoters; therefore, they are not ideal models
for developing tissue-specific aromatase inhibition strat-
egies (12, 18).
In premenopausal women, the ovaries express high lev-
els of aromatase and are the main source of estrogens.
However, extragonadal aromatase expression plays a key
role in estrogen production, especially in men and post-
menopausal women, because ovarian aromatase expres-
sion ceases after menopause (11). Estrogens synthesized
locally in extragonadal sites do not typically enter the cir-
culation; rather, local estrogens exert intracrine, auto-
crine, paracrine, and juxtacrine effects, acting directly on
cells and tissues. These effects are very difficult tomeasure
in the clinical setting, and they remain mostly
unrecognized.
We and others have proposed that adipose tissue aro-
matase is the major determinant of local levels of estrogen
in the breast and is linked to breast cancer risk (19, 20).
Because female mice lack the promoters for aromatase
expression in extragonadal tissues, such as the breast ad-
ipose, we generated a transgenic humanized aromatase
(Aromhum) mouse line that contains a single copy of the
human aromatase gene and mimics human physiology
with respect to tissue-specific patterns of aromatase ex-
pression and estrogen production.Herewe report themo-
lecular and functional aspects of humanized aromatase
expression in the mammary gland and other peripheral
tissues in the Aromhum mice and the potential application
for the study of the relationship between breast aromatase
expression, estrogen production, obesity, and breast can-
cer pathology.
Materials and Methods
Bacterial artificial chromosome (BAC) clones
characterization and generation of transgenic mice
Three BAC clones were obtained from the BACPAC Re-
sources Center of Children’s Hospital Oakland Research Insti-
tute (Oakland,CA). BACDNAwas transformed into competent
bacteria (DH10B) and grown in Luria-Bertani medium contain-
ing 12.5 g/ml chloramphenicol. BAC DNA was extracted by
the alkaline lysismethod. The sizes of the BACwere estimated by
NotI linearized restriction digestion and 0.6% agarose gel elec-
trophoresis. The ends of the BAC were sequenced, and a large-
scale EcoRV restriction map was generated (data not shown).
Aromatase gene integrity was confirmed with PCR primer pairs
that hybridize to its promoter regions (I.1, I.4, I.7, I.f, I.6, I.3, and
PII) and coding region (exon II and exonX; data not shown) (21,
22). One of the BAC clones (RP11–1134K1) contained the com-
plete aromatase locus and was subsequently used for all studies.
Linearized RP11-1134K1 DNAwas microinjected into the pro-
nucleus of strain FVB/N-fertilized oocytes at the Baylor College
ofMedicineGeneticallyEngineeredMouseCore (Houston,TX).
Integration of the transgene in the offspringwas assessed by PCR
analysis. The primer sequences used for screening PCR are listed
in Supplemental Table 1, published on The Endocrine Society’s
Journals Online web site at http://endo.endojournals.org.
Genotyping and animals
Genotypic analyses were performed by PCR using genomic
DNA isolated from the tails of potential founder mice. Initial
genotyping was done using the PCR primers described above.
Similar phenotypes of mammary hyperplasia were observed in
two independent transgenic lines, F1771 and F1772. Both lines
contained the complete human aromatase coding region. The
F1771 line contained a longer promoter region, starting 75 kb
upstream of the ATG translation start site and including pro-
moters I.4, I.7, I.f, I.6, I.3, and PII. The F1772 line contained a
shorter promoter region, starting 4.3 kb upstream of the trans-
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lation start site and including promoters I.6, I.3, and PII. Mice
were maintained on a 14-h light, 10-h dark cycle, with standard
chow (7912; Harlan Teklad, Madison, WI) and water available
ad libitum. Animals were housed according to the National In-
stitutes of Health Guide for the Care and Use of Laboratory
Animals. All procedures were approved by the Animal Care and
Use Committees of Baylor College of Medicine and Northwest-
ern University. All tissues and serum were collected from mice
between1000and1200h to remove variability in daily hormone
fluctuations.
RNA isolation and quantitative real-time PCR
Total RNA from various mouse tissues was extracted at 24
and 64 wk of age using TRIzol reagent according to the manu-
facturer’s instructions (Sigma, St. Louis, MO). cDNA was re-
verse transcribed using oligo(deoxythymidine) primers and a re-
verse transcriptase kit (Invitrogen Corp., Carlsbad, CA). Real-
time PCR was performed with the Taqman and Power SYBR®
green PCR master mix kit according to the manufacturer’s in-
structions (Applied Biosystems, Foster City, CA) in an ABI
7900HT fast real-time PCR system (Applied Biosystems). The
primer sequences used for real-time PCR are listed in Supple-
mental Table 1. Real-time PCR cycler conditions were: 50 C for
2 min, 95 C for 10 min, and 40 cycles of 95 C for 15 sec and 60
C for 1 min. PCR results were normalized to mouse glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) gene expression
(23). Cycle threshold values at or above 40 cycles were consid-
ered to be below the level of detection.
5-Rapid amplification of cDNA ends (RACE)
To determine the transcriptional start sites of human aroma-
tase transcripts from various tissues, 5-RACE was performed
using the SMART RACE cDNA amplification kit (CLON-
TECH, Mountain, CA) as described previously (12). The pri-
mary touchdown PCR reverse primers used were as follows:
mouse touchdown reverse primer (5-GACTCTCAT-
GAATTCTCCATACATCT-3) and human touchdown reverse
primer (5-GTCCAATTCCCATGCAGTAGCCAGGA-3). If
the primary PCR reaction failed to give the distinct bands of
interest, a secondary, or nested PCR was performed with the
mouse nested reverse primer (5-AATGAGGGGCCCAATTC-
CCAGA-3) and human nested reverse primer (5-CCAA-
GAGAAAAAGGCCAGTGAGGAGCA-3). RACE products
were cloned into the pCR-TOPO TA cloning vector and subse-
quently sequenced.
Exon-specific RT-PCR amplification
Total RNAwas extracted from24-wk-old left inguinalmam-
mary gland (gland no. 4), and cDNA was synthesized using oli-
go(deoxythymidine) primers with a reverse transcriptase kit (In-
vitrogen, Camarillo, CA). To amplify the human transcript
variants in themammary gland (drivenbypromoters PII, I.3, and
I.4), we used forward primers designed to hybridize to the dif-
ferent 5-untranslated regions of each transcript and a reverse
primer that hybridized to coding exon III (24). The PCRwas run
as follows: 4 min at 95 C, followed by 35 cycles of 30 sec at 94
C, 30 sec at 60 C, and 1 min at 72 C, and a final extension of 9
min at 72 C.
Whole mounts, tissue histology, and
immunohistochemistry
Themorphologyof themammary glandswas examinedusing
the whole-mount technique (25). Glands were spread on glass
slides, fixed, and subjected to carmine (Sigma Chemicals) stain-
ing. To prepare mammary gland sections, inguinal glands were
removed from mice, fixed in 4% phosphate-buffered parafor-
maldehyde overnight, and then transferred to 70% ethanol. Tis-
sues were embedded in paraffin and sectioned at 5 m. After
deparaffinization, rehydration, and antigen retrieval by heating
in antigen unmasking solution (Vector Laboratories, Burlin-
game,CA), primary antibodies [human aromatase (1:100,MCA
2077); AbD Serotec, Oxford, UK; or Ki67 antibody (1:200,
ab66155); Abcam, Cambridge, MA] were applied to the sec-
tions. After incubation at 37 C for 1 h or 4 C overnight, the
sectionswerewashedwithPBSand incubatedwithabiotinylated
horse-antimouse secondary antibody (1:600, BA-2000;Vector
Laboratories) at 37 C for 30 min followed by avidin-biotin-
horseradish peroxidase complex (Vector, Laboratories). Sec-
tionswere examinedusing aZeissAxio Scopemicroscope (Zeiss,
Gottingen, Germany) (26).
Protein extraction and immunoblotting
Mammary gland total protein was extracted in a buffer con-
taining 10 mmol/liter Tris (pH 7.4), 150 mmol/liter NaCl, 1
mmol/liter EDTA, 1mmol/liter EGTA, 0.5%Nonidet P-40, pro-
tease inhibitors (2 mmol/liter phenylmethylsulfonyl fluoride, 10
mg/ml leupeptin, and 10 mg/ml aprotinin), and phosphatase in-
hibitors (100 mmol/liter sodium fluoride, 10 mmol/liter sodium
pyrophosphate, and 2 mmol/liter sodium orthovanadate). Ly-
sates were centrifuged at 50,000  g for 60 min at 4 C. Protein
concentrations were determined using the bicinchoninic acid
protein assay (Pierce, Rockford, IL) according to the manufac-
turer’s instructions. Samples containing 25 g of protein were
boiled for 4min in a reducing Laemmli sample buffer containing
80 mmol/liter dithiothreitol and subjected to electrophoresis on
10% sodium dodecyl sulfate-polyacrylamide gels. Proteins were
then transferred from gels to nitrocellulose membrane. The
membranes were blocked with 5% insulin-free BSA in TBS-
Tween 20, and proteins were detected using various antibodies
[phospho-Stat5 (1:500, 71-6900) and Stat5a (1:1000, 13-3600)
antibodies (Invitrogen); -casein (H-7) antibody (1:500, sc-
166520) (SantaCruz Biotechnology, SantaCruz, CA); and-ac-
tin antibody (1:6000, A1978) (Sigma Chemicals)]. After exten-
sive washings, the immune complexes were detected with
horseradish peroxidase conjugated with specific secondary an-
tiserum [(1:5000, antirabbit IgG (7074), antimouse IgG (7076);
Cell Signaling Technology, Inc., Danvers, MA)] followed by an
enhanced chemiluminescence reaction. The blots were analyzed
by densitometry and quantified withMultiGauge software (Fuji
PhotoFilm, Valhalla, NY).
Serum and tissue hormone levels
Blood sampleswereobtained from the retroorbital veinor tail
vein. Serum estradiol (E2) was measured by ELISA (ES 180S;
Calbiotech Inc., Spring Valley, CA), serum testosterone, proges-
terone, and FSH levels weremeasured by RIA, and LHwasmea-
sured by immunoradiometric assay by the University of Virginia
Center for Research in Reproduction LigandAssay andAnalysis
Core (Charlottesville, VA) (27–30). The mouse LH and FSH
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assays are in the Methods section of the web site of this facility
(http://www.medicine.virginia.edu/research/institutes-and-pro-
grams/crr/lab-facilities/assay-methods-page). Estrogens [estrone
(E1) and E2] and estrogen metabolites [2-methoxyestrone
(2ME1), 2-methoxyestradiol (2ME2) and estriol (E3)] in serum
and the mammary gland were determined by liquid chromatogra-
phy-tandem mass spectrometry (LC-MS2) at the National Cancer
Institute/National InstitutesofHealth, asdescribedpreviously (31).
Serum prolactin levels were measured by bioassay (32). The deter-
mination of the stage of the estrous cycle was made by vaginal
smears. To measure serum E2 levels by ELISA at various stages of
the estrous cycle (Calbiotech), serum from 6.5-wk-old mice was
collected for 8–9 consecutive days from the tail vein.
Superovulation
Pregnant mares’ serum gonadotropin (PMSG) and human
chorionic gonadotropin (HCG)wasobtained fromSigmaChem-
icals. Ten 8-wk-old mice for each genotype [wild type (WT),
F1772, F1771] were injected ip with 5 IU PMSG. Forty-eight
hours after the PMSG injection, five of each genotypewere killed
and ovaries were collected. The other five were injected ip with
5 IUHCG. Sixteenhours after theHCG injection, the second five
mice were killed and ovaries were collected for the further in-
vestigation. Five 8-wk-old mice for each genotype were injected
with vehicle alone as controls.
Vaginal opening and estrous cyclicity
Beginning 10 d after birth, females were examined daily for
the onset of vaginal opening. To examine various stage of the
estrous cycle, vaginal lavages with 0.9%NaCl from female mice
(6.5–8 wk old) were obtained and viewed under a microscope
daily between 0900 and 1000 h for at least two cycles (8–9
consecutive days). A normal estrous cycle was defined as 2 d of
leukocytic cytology followed by 1 d of nucleated and 1–2 d of
cornified cytology.
Statistical analysis
Results are expressed as mean  SE. Statistically significant
differences at P  0.05 were determined using a one-factor
ANOVA followed by a t test.
Results
Generation of the transgenic Aromhum mouse
To develop an animal model in which the human aro-
matase gene is regulated via its tissue-specific alternative
promoters in various tissues, we first screened and ob-
tained a human BAC clone containing the human aroma-
tase coding sequence flanked by its full-length, 93-kb 5-
regulatory region and the 3-polyadenylation site. We
injected a single copy of the BAC clone into pronuclear
mouse embryos to generate the Aromhum transgenic
mouse line. PCR primers designed to amplify the human
aromatase coding region and the major promoter se-
quences were used to identify six initial founders contain-
ing the transgene. A schematic of the human BAC clone
construct used to generate the Aromhum line and a repre-
sentative PCRof genomicDNAfrom twoof the six found-
ers (F1772 and F1771) are shown in Fig. 1A. Both F1772
and F1771 harbored the full (30 kb) coding region and its
3 end. F1772 had a 4.3-kb 5-flanking region containing
only the proximal promoters I.6 and I.3/II,whereas F1771
included a greater than 78-kb 5-flanking region encom-
passing the more distal promoters I.4, I.7, and I.f as well
as promoters I.6 and I.3/PII (Fig. 1A). As in humans, the
encoded aromatase protein was identical in both found-
ers, regardless of the promoters present in the transgene.
To determine the aromatase mRNA expression profile
in female Aromhum mouse tissues, 24-wk-old mice were
euthanized and multiple tissues were collected and ana-
lyzed using real-time RT-PCR (Table 1). Consistent with
patterns of extragonadal aromatase expression inwomen,
human aromatase mRNA was detected in the ovary, hy-
pothalamus, pituitary, uterus, mammary gland, aorta,
lung, stomach, adrenal gland, bladder, gonadal fat, sc fat,
andabdominalmuscle inbothF1771andF1772Aromhum
mouse lines and in the quadriceps muscle, brown adipose
tissue, heart, liver, spleen, intestine, kidney, and bone in
the F1771 line (Table 1). We used 5-RACE to detect pro-
moter-specific mRNA species. The term present denotes
only the amplification of the coding region of human aro-
matase mRNA species by real-time PCR; we were, how-
ever, unable to detect promoter-specific 5-untranslated
regions in these tissues using 5-RACE. If 5-RACE pro-
duced a promoter-specific mRNA, this promoter was in-
dicated in Table 1. Mouse aromatase mRNA in the ovary
and brain was similar between WT and Aromhum mice
(Supplemental Fig. 1). In the ovary aromatase is mainly
expressed ingranulosa cells.Aromhummice showed strong
expression of human aromatase mRNA in the ovary. We
used PMSG in conjunction with HCG to superovulate
female mice. Both mouse and human aromatase mRNA
levels were significantly increased in WT, F1772, and
F1771 mice after administration of PMSG for 48 h and
significantly decreased in all mice after HCG injection for
16 h compared with PSMG treatment (Fig. 1, B and C).
These data demonstrated that both the aromatase trans-
gene and endogenous aromatase have a similar expression
pattern. The endogenous mouse aromatase was lower in
PMSG-treated F1772 mice as compared with PMSG-
treated WT and F1771 mice but was higher compared
with vehicle-treated F1772 mice (Fig. 1, B and C). Thus,
the human transgene did not change the general pattern of
endogenous aromatase expression. To determine the fer-
tility/reproductive function of Aromhum mice, transgenic
andWT females were mated withWTmales. The average
litter size between WT and Aromhum mice was similar
(Fig. 1D). Ovarian appearance, including the number of






/endo/article-abstract/153/6/2701/2423948 by guest on 26 N
ovem
ber 2019
corpus lutea (ovulation), was similar between WT and
Aromhum mice (data not shown).
Expression of human aromatase in mammary
adipose fibroblasts and myoepithelia of Aromhum
mice via its cognate promoters PII, I.3, and I.4
We next analyzed each of the transgenic lines for the
expression andpromoter usage of aromatase inmammary
gland. Total RNA was isolated from biopsies of inguinal
mammary glands (no. 4) from 24-wk-old Aromhum and
WT littermates. In Aromhum mice, we found human aro-
matase expression inmammary gland and that the level of
human aromatase mRNA was significantly higher in
F1771 mice than that in F1772 mice (Fig. 1E). Human
aromatase mRNA was not detected in the WT mammary
glands. We then used exon-specific RT-PCR to determine
promoter usage in the mammary gland of Aromhum mice
and found that human aromatase expression was driven
by PII, I.3, and I.4 in F1771mice and by I.3 in F1772mice
(Fig. 1F). We used immunohistochemistry to localize hu-
man aromatase within the mammary gland of Aromhum
mice; as expected, human aromatase immunostainingwas
absent inWTmice. In 24-wk-old Aromhum mice, staining
was observed in adipose fibroblast cells andmyoepithelial
cells but absent in epithelial cells (Fig. 1G).
Increased local estrogen concentration in the
breast tissue of Aromhum mice
To determine whether elevated human aromatase ex-
pression in the Aromhum mouse mammary tissue is ac-
FIG. 1. Generation and characterization of the Aromhum transgenic mouse line. A, Schematic of the human BAC clone construct used to generate
Aromhum transgenic mice. RT-PCR showed transmission of the transgene to the germline. F1772 contained exons PII, I.3, and I.6. F1771 contained
all first exons of the aromatase gene except I.1. Mouse (B) and human (C) aromatase mRNA levels in ovaries of superovulated mice are shown.
Females were given one of the following: 1) PMSG for 48 h, 2) PMSG for 48 h followed by HCG for 16 h, or 3) vehicle (Veh) alone. Ovaries were
collected after treatment for the further analysis as described in Materials and Methods (n  5 mice per group). #, P  0.05 vs. vehicle; *, P 
0.05 vs. PMSG. D, Average litter size of Aromhum or WT females mated to WT males (n  8 mice per group). E, Human aromatase mRNA was
expressed in the mammary glands of Aromhum mice. *, P  0.05. F, Exon-specific RT-PCR confirmed the different promoter driven human
aromatase expression in the mammary gland of Aromhum mice. GAPDH mRNA levels served as the control. Data are representative of three
independent experiments. G, Immunohistochemical localization of human aromatase in the mammary glands of Aromhum mice (n  4–5 mice per
group). Arrows indicate aromatase positive staining. Bar, 50 m.
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companied by increased tissue estrogen levels and change
in circulating hormone levels, we comparedmammary tis-
sue E2 levels and peripheral serum levels of estrogens, pro-
gesterone, testosterone, prolactin, and the gonadotropins
LH and FSH using ELISA and RIA technologies (Fig. 2).
Serum E2 levels were similar between WT, F1772, and
F1771 females (Fig. 2A), as were those in the mammary
tissue (data not shown). However, serum LH concentra-
tions were lower in F1771 by 57 and 37%, respectively,
compared with WT and F1772 females (Fig. 2B). The de-
creased LH in the F1771 line also accounted for the sig-
nificantly lower serum testosterone levels (Fig. 2D) and a
nonsignificant trendof lower progesterone levels in F1771
females (Fig. 2E) because LH regulates ovarian progester-
one secretion. Serum concentrations of FSH and prolactin
remained unchanged between WT,
F1772, and F1771 littermates (Fig. 2, C
and F).
Because serum concentrations mea-
sured by ELISA of the biologically ac-
tive estrogen, E2, were not different be-
tweenWT, F1772, and F1771mice, we
applied a much more sensitive technol-
ogy, LS-MS2, to measure the total se-
rumconcentrations of the estrogens (E1
and E2) and its metabolites (E3, 2ME1,
and 2ME2). Serum E1 levels were
slightly but significantly increased in
F1772 and F1771 mice compared with
WT mice (Fig. 3A). Serum E2 and E3
levels were also modestly but signifi-
cantly higher in F1772 mice compared
with WT mice (Fig. 3A). However, the
total levels of estrogenswere similar be-
tweenWT, F1772, and F1771 females,
FIG. 2. Serum testosterone and LH levels are lower in Aromhum mice compared with WT
littermates. Mouse sera were collected from 24-wk-old mice. Serum E2 (A), LH (B), FSH (C),
testosterone (D), progesterone (E), and prolactin (F) were measured by ELISA, RIA, or bioassay
(n  11–12 mice per group). *, P  0.05 vs. WT mice.
TABLE 1. mRNA expression profile of human aromatase in various tissues of 24-wk-old female Aromhum mice
Tissues (n  3)
WT F1772 F1771
H Arom M Arom H Arom M Arom H Arom M Arom
Ovary  Pgon PII Pgon PII Pgon
Hypothalamus  Pbr Present Pbr I.f Pbr
Pituitary   Present  Present- 
Nonpregnant uterus   Present  Present- 
Mammary gland   PII/I.3  PII/I.3/I.4 
Aorta   Present  I.4 
Lung   Present  I.4 
Stomach   Present  Present- 
Adrenal gland   Present  Present- 
Bladder   Present  I.4 
Gonadal fat   Present  Present- 
Subcutaneous fat   Present  Present- 
Abdominal muscle   Present  I.4 
Quadriceps muscle     I.4 
Brown adipose     Present- 
Heart     Present- 
Liver     Present- 
Spleen     Present- 
Intestine     I.7/I.f 
Kidney     Present- 
Bone     I.4 
Quantitative real-time RT-PCR was used to determine the presence or absence () of mouse and human aromatase mRNA in various tissues of WT
mice and lines F1772 and F1771. 5-RACE identified mRNA transcribed from each promoter (PII, I.f, I.4, I.3) in the human aromatase transgene or
native mouse promoters. Pgon, Mouse gonadal aromatase promoter; Pbr, mouse brain aromatase promoter; H Arom, human aromatase; M Arom,
mouse aromatase.
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which concurred with E2 levels measured by ELISA (Fig.
2A). Serum 2ME1 levels were significantly decreased and
2ME2 levels were significantly increased in F1772 and
F1771 mice compared with WT mice.
To determine the functionality of human aromatase
transgene and production of estrogens in the mammary
gland, we also measured the local levels of mammary es-
trogens and their metabolites using LS-MS2 (Fig. 3B). To-
tal mammary estrogen levels were significantly higher in
F1772 by 1.8-fold and in F1771 by 2.5-fold, compared
with WT mice (Fig. 3B). Compared with WT mice, E1
levelswere 3.1-fold higher in F1772 and 3.8-fold higher in
F1771 mice; E2 levels were 1.4-fold higher in F1772 and
2.4-fold higher in F1771 mice; and 2ME2 levels were sig-
nificantly higher in F1772 and F1771mice (P 0.05). No
differences in mammary E3 or 2ME1 levels were observed
between WT, F1772, and F1771 mice (Fig. 3B). ER and
progesterone receptor (PR) mRNA levels did not differ
between WT, F1772, and F1771 mice (Fig. 3, C and D).
Increased ductal elongation and outgrowth during
puberty in Aromhum mice
E2 has been shown to act directly on the mammary
gland to stimulate ductal elongation during puberty (33).
To determine whether expression of human aromatase in
the mammary gland affects ductal morphogenesis, we ob-
served mammary morphological changes in mice at 5, 7,
or 12 wk of age. At 5 wk of age (prepubertal), the size and
morphology of themammary glands fromWTandArom-
hummicewere similar (Fig. 4C). At 7wk of age (equivalent
to puberty), mammary tissues from
bothWT and Aromhum showed similar
morphological changes, with promi-
nent duct elongation and a few alveoli
growing from terminal branches at the
end buds; however, ductal outgrowth
was accelerated in F1771 mice com-
pared withWTmice. We measured the
ductal length from the mammary
lymph node to the tip of the terminal
end buds in 7-wk-old mice and found
that mammary ducts of F1771 mice
were significantly longer than those of
WT mice (Fig. 4, A and B). Mammary
gland morphology and ductal elonga-
tion were similar in WT and Aromhum
mouse lines at 12 wk of age (postpu-
bertal, Fig. 4C). The vaginal opening,
an external marker for the onset of pu-
berty, was first observed at similar ages
inWT, F1772, and F1771mice (29.8
0.4, 30 0.8, and 29.2 0.4 d, respec-
tively; n 6, Fig. 4D). These data sug-
gest that the observed increase in ductal length in the
F1771 lines cannot be explained by early puberty. Serum
E2 levels at the proestrous stage ofWT and Arom
hummice
were significantly higher than the serum E2 levels at di-
estrous or estrous stages. However, the serum E2 levels
were not different between WT, F1772, and F1771 mice
within the same estrous stage (Fig. 4E). This result sug-
gested that the accelerated ductal growth at puberty is not
secondary to increased serum estrogen levels but more
likely due to excess local estrogen production in the mam-
mary gland.
Mammary aromatase expression and estrogen
production are associated with mammary
hyperplasia in Aromhum mice
We showed that the Aromhummice express human aro-
matase in several peripheral tissues, including breast fat,
under the control of alternative promoters and produce
estrogen in the mammary glands, mimicking human pat-
terns of extraovarian estrogen production. To determine
the effects of local estrogenonbreast tissue in theAromhum
mouse, we analyzed mouse mammary morphology and
histology at 24 and 64wk of age. Figure 5A showswhole-
mount stainingofmammaryglandsat24wkofage.Virgin
WT females exhibited normal mammary ductal morpho-
genesis as reflected by the presence of an ordered ductal
network with normal side branching. In contrast, virgin
Aromhum mice displayed disseminated mammary gland
hyperplasia indicated by excessive ductal side branching
FIG. 3. Mammary unconjugated estrogens are higher in Aromhum mice compared with WT
littermates. Serum (A) and mammary gland (B) unconjugated estrogens and estrogen
metabolites were measured by LC-MS2 assay. E1, E2, E3, 2ME1, and 2ME2 are shown. mRNA
levels of ER (C) and PR (D) were measured by real-time RT-PCR (n  15 mice per group).
*, P  0.05 vs. WT mice.
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and by the development of aberrant lobular structures.
However, mammary gland hyperplasia was reduced evi-
denced by decreased ductal side branching in F1772
mice as compared with F1771 mice. Mammary glands
in Aromhum mice (F1772 and F1771 lines) showed a
marked increase in lobuloalveolar hyperplasia and exhib-
ited extensive lipid droplets at 24 wk compared with WT
mice (Fig. 5B). Keratinizing hyperplasia was also seen in
mammary glands of F1771 females (data not shown). The
percent of mice in each group showing hyperplasia was
5-fold higher in F1771 mice and 3-fold higher in F1772
mice compared with WT mice (Fig. 5C). We also investi-
gatedwhether the lobuloalveoli in theAromhummicewere
functional by measuring the expression levels of various
milk-specific mRNA transcripts and protein during preg-
nancy (34). -casein mRNA levels were significantly in-
creased in F1771 mice compared with WT and F1772
mice; however, WDNM1 (also called extracellular pro-
teinase inhibitor or Expi) mRNA levels were similar be-
tween WT, F1772, and F1771 mice
(Fig. 5, D and E). To minimize differ-
ences onmammary glandhistology and
milk protein levels resulting from the
estrous cycle, postmenopausal female
(64 wk old) mammary glands were an-
alyzed. Lobuloalveolar hyperplasia in
Aromhum mice had a similar appear-
ance at both 24 and 64 wk old (Fig. 5,
B and F). However, the percent of mice
exhibiting hyperplasia was higher in
WT and F1772 mice at 64 wk of age
comparedwith that at 24wkof age and
similar in 1771mice between24 and64
wk old (Fig. 5, C and G). Milk protein
-casein was significantly increased in
64-wk-old Aromhum as compared with
the WT littermates (Fig. 5H).
Mammary hyperplasia is induced
by epithelial hyperproliferation in
Aromhum mice
We observed a significantly higher
epithelial cell content in the mammary
glands of Aromhum mice compared
withWTmice, which may be due to an
increase in estrogen-stimulated epithe-
lial proliferation. We performed Ki67
immunohistochemical analysis to com-
pare the level of epithelial cell prolifer-
ation in the mammary glands of WT
and Aromhum mouse lines. The num-
bersofKi67-positivenuclei in themam-
mary epithelium of Aromhum mouse
lineswere significantly higher than those inWTmice at 24
wk of age (Fig. 6, A and C). Specifically, the percentage of
Ki67-positive nuclei was 4.8-fold and 2.8-fold higher in
the mammary epithelium of F1771 and F1772 mice, re-
spectively, compared with WT mice (P  0.05 for both).
We performed Ki67 immunohistochemistry in postmeno-
pausal female mice (64 wk old) to preclude the variation
resulting from the estrous cycle. The percentage of Ki67-
positive nuclei was similar between 24- and 64-wk-old
WT, F1772, and F1771 mice (Fig. 6, B and D).
Mammary aromatase expression is associated with
phosphorylation of Stat5 in Aromhum mice
To better understand the activated signaling pathways
associated with increased local estrogens production in
breast tissue displaying hyperplasia and lipid droplets, we
used immunoblotting to determine protein phosphoryla-
tion in mammary glands of 24-wk-old females. Previous
FIG. 4. Increased mammary ductal elongation during puberty in F1771 Aromhum mice
compared with WT mice. A, Whole-mount staining was performed on mammary glands from
WT, F1772, and F1771 mice at 7 wk of age. Glands were spread on glass slides, fixed, and
subjected to carmine staining. Bar, 1000 m. B, The length of mammary ducts from 7-wk-old
(B) and 5- and 12-wk-old females (C) were measured from the lymph node to the tip of the
terminal end buds. D, The time of vaginal opening in Aromhum mice was not different from
littermate controls (n  6 mice per group). E, Serum E2 levels were measured based on cycle
stage. The 6.5-wk-old mice were bled for 8–9 consecutive days. Cycle stage was determined
by vaginal cytology (n  10–11 mice per group). *, P  0.01 vs. diestrous stage; #, P  0.05
vs. proestrous stage.
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studies showed that estrogens, via binding to cytoplasmic
ormembrane receptors, rapidly activated intracellular sig-
naling cascades such as Stat, ERK, or PI3K/Akt (35, 36).
As shown in Fig. 7, A and B,Western blot analysis showed
a significant increase in Stat5a phosphorylation in breast
tissue of F1771 mice compared with WT mice at the age
of 24 wk. Stat5 phosphorylation in postmenopausal fe-
males (64 wk) was measured to preclude possible cycle
stage-dependent variations. Similar differences were ob-
served between 24-wk-old and 64-wk-old mice (Fig. 7, C
and D). Stat5a phosphorylation in F1772 mice was also
increased at 24 and 64 wk of age, but this difference was
not statistically significant. Phosphorylation of ERK or
Aktwasnotdetectable inWT,F1772, orF1771mice (data
not shown).
Discussion
We and others have shown that two distinct promoters
control aromatase expression in the ovary and brain of
female mice (12–14). However, additional alternative
promoters regulate aromatase expression in many ex-
tragonadal tissues (e.g. fat in breast, bone, and lung) in
women (11, 37). To mimic the human aromatase expres-
sion patterns and physiology related to local estrogen pro-
duction in various tissues, we generated Aromhum mouse
lines containing a single copy of the human aromatase
gene driven by its native tissue-specific promoters. The
aromatase expression pattern in Aromhum mammary
stroma andmyoepithelia mimicked human aromatase ex-
pression in basal and stromal cells in human breast tissues
(38).TheAromhummiceproduced excessive local estrogen
in breast tissue and displayed mammary lobuloalveolar
hyperplasia at 24 and 64wk. This newmousemodel is the
first of its kind. We predict that it will be a valuable tool
for developing tissue-specific aromatase inhibition
strategies.
The mammary gland undergoes most of its branching
during adolescence rather than during fetal development.
Hormone-dependent branching requires estrogen and
ER expression in the breast (33). In this study, human
aromatase expression in mouse mammary stroma and
myoepithelia was associatedwith increased local estrogen
production and increased ductal elongation and out-
growth in the mammary gland during puberty compared
with WT littermates. However, WT and Aromhum mice
had similar levels of serum estrogens, suggesting an im-
portant role of local excessive mammary tissue estrogens
in stimulating linear ductal growth at puberty. These re-
sults are inconsistent with previous reports that described
FIG. 5. Mammary lobuloalveolar hyperplasia in the Aromhum mouse. A, Whole-mount staining was performed on mammary glands from WT,
F1772, and F1771 mice at 24 wk of age (n  5 mice per group). Bar, 1000 m. B, Hematoxylin and eosin (H&E) staining was performed on 24-
wk-old mammary gland tissue from WT, F1772, and F1771 mice (n  4 or 5 mice per group). Bar, 50 m. C, Percentage of mice showing
mammary hyperplasia was determined based on H&E staining of mammary glands from 24-wk-old mice (n  11 mice per group). mRNA
expression of milk proteins WDNM1 (D) and -casein (E) in mammary glands of WT and Aromhum mice was measured by real-time RT-PCR and
normalized to GAPDH mRNA levels (n  4 mice per group). *, P  0.05 vs. WT mice. F, H&E staining was performed on 64-wk-old mammary
gland tissue from WT, F1772, and F1771 mice (n  4 or 5 mice per group). Bar, 50 m. G, Percentage of mice showing mammary hyperplasia
from 64-wk-old mice (n  5 mice per group). H, Milk protein -casein was measured by Western blotting in WT and Aromhum mice at 64 wk of
age (n  3–4 mice per group).
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a role of systemic estrogen rather than local estrogen in
controlling mammary side branching (39).
Aromatase converts the androgens testosterone andan-
drostenedione into E2 and E1, respectively. As expected,
humanized aromatase expression decreased systemic tes-
tosterone levels in the Aromhum mice, which was most
likely caused by suppression of LH by the additional local
production of estrogen driven by human aromatase ex-
pressed in the brain. Peripheral human aromatase expres-
sion probably does not account for the decreased testos-
terone in F1771 females because peripheral conversion of
testosterone to E2 is estimated to be approximately 1%
(11). A previous study showed that estrogens induced PR
expression and increased pituitary prolactin concentra-
tion (39, 40). However, in the present study, additional
estrogen production from the human aromatase gene did
not change circulating levels of prolactin, progesterone or
FSH nor did this effect on mRNA levels of PR or ER in
the mammary gland. These results suggest that elevated
tissue estrogen production exerts selective effects on cer-
tain endocrine systems.
The Aromhum mice, containing a single copy of the en-
tire human aromatase gene, mimicked human aromatase
expression pattern in mice and thus human physiology
with respect to estrogen production (41). This Aromhum
mouse model is unique and offers new opportunities for
studying estrogen-related physiology for the following
reasons. Because the Aromhum mice were generated via
autosomal insertion of a single copy of the entire human
aromatase gene, it produces physiological amounts of es-
trogen in relevant mouse tissues. Second, the tissue distri-
bution pattern of human aromatase expression in Arom-
hum females is nearly identical with that observed in
women. Third, physiologically relevant native promoters
control the human aromatase gene in a tissue-selective
fashion. Fourth, the physiological genetic mechanisms
such as binding of transcriptional activator or silencer
complexes to the native chromatin leading to alternative
FIG. 6. Cell proliferation evaluated by Ki67 staining is higher in mammary epithelia of Aromhum mice compared with WT littermates. Ki67-positive
nuclei were detected at 24 wk (A) and 64 wk (B) of WT, F1772, and F1771 mice by immunostaining using an antibody against Ki67 (arrows). Bar,
50 m. A total of 2000 nuclei were counted in sections obtained from mice at 24 wk (C) and 64 wk of age (D) to calculate the percent of Ki67-
positive nuclei in WT and Aromhum mice (n  3–4 in each group). *, P  0.05 vs. WT.
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activationofpromoters, alternative splicingof anuntrans-
lated first exon to a common splice junction, and the rest
of the splicing events leading mRNA transcription and its
polyadenylation, all operate in a seemingly identical fash-
ion to that observed in the human body. Finally, the cel-
lular distribution of the aromatase expression in themam-
mary tissue of mice matched our previously published
observation in women (42).
The insertion of a single copy of the human aromatase
gene into female mice gave rise to a remarkably increased
frequency of lobuloalveolar hyperplasia in the mammary
tissue, which was accompanied by increased mammary
epithelial proliferation at 24 wk of age. Although these
findings may be associated with an increased risk of ma-
lignancy in the long term, the incidence of mammary can-
cer in thesemice is currently unknown. Itmaybenecessary
to facilitate carcinogenesis chemically or by crossing these
mice with a mildly tumorigenic genetic strain to assess the
role of the human aromatase gene in mammary carcino-
genesis. This will be an active area of research in our
laboratory.
Prolactin plays a primary role in the physiological pro-
cess ofmammarygland secretion through the activationof
various signaling cascades including Janus kinase-2/Stat5,
ERK, and PI3K/Akt (43). Stat5 was first found to be in-
volved in the prolactin-induced -casein gene expression
in mammary glands (44). Here we observed lipid droplet
accumulation in the mammary glands of Aromhum mice.
However serum prolactin levels were similar in WT and
Aromhum mice. Previous studies have shown that estro-
gens, via binding to cytoplasmic or membrane receptors,
rapidly activated intracellular signaling cascades such as
Stat, ERK, or PI3K/Akt (35, 36). Stat5a phosphorylation
was significantly increased in breast tis-
sue of F1771 mice compared with WT
mice. However, not every mouse
showed the increased of Stat5 phos-
phorylation. This may be due to ex-
pected variations in gene expression
and signal transduction in transgenic
mice, which are frequently encoun-
tered. These data suggested that local
increased E2 could activate Stat5 and
that this could be a mechanism for
mammary hyperplasia and lipid drop-
let accumulation.
The side effects observed during
treatment with the aromatase inhibi-
tors are the result of global inhibition of
the aromatase activity in all tissues (18,
45, 46). Thus, the ideal therapeutic ap-
proach to treatment of estrogen-re-
sponsive breast cancerswould be the tissue-specific block-
age of estrogen production in the breast only. The
development of tissue-selective aromatase inhibitors is
plausible because of the tissue-specific regulation of aro-
matase expression (47, 48). Inhibition of promoter II/I.3-
mediated transcription might provide a breast-specific
therapy (20, 49); therefore, factors regulating transcrip-
tion from these promoters are currently being studied. Be-
cause aromatase expression in the Aromhummodel closely
resembles that in humans, the model may be useful for
identifying signaling pathway inhibitors that can block
aromatase expression arising from promoters II and I.3
butpermit the activationofpromoters I.f, I.4, and I.6.This
would lead to the inhibition of all estrogen synthesis in the
ovary and the majority of estrogen synthesis in the mam-
mary gland but permit local estrogen production in the
brain, bone, and at low levels in fat. This approach would
be sufficient to inhibit mammary hyperplasia and carci-
nogenesis while maintaining the beneficial effects of es-
trogen in other tissues. Such an approach may lead to
viable treatment options with fewer side effects compared
with the currently available aromatase inhibitor that
causes whole-body estrogen deprivation. Our in vivo
Aromhum model would be ideal for screening candidate
selective aromatase inhibitors.
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